Accord has failed to clear the way for its planned UK generic Entresto launch after the UK High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.
Accord has failed to clear the way for its planned UK generic Entresto launch after the UK High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.